Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease–Associated Interstitial Lung Disease

OBJECTIVE: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in connective tissue diseases (CTDs). We aimed to assess the effect of rituximab ± mycophenolate mofetil (MMF) compared with MMF on pulmonary function and prednisone dosage in patients with CTD‐related ILD (CTD‐IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lisa, Chung, Melody P., Gagne, Laurence, Guo, Haiwei H., Guenther, Zachary, Li, Shufeng, Jacobs, Susan, Morisset, Julie, Mooney, Joshua J., Raj, Rishi, Chung, Lorinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811692/
https://www.ncbi.nlm.nih.gov/pubmed/33274857
http://dx.doi.org/10.1002/acr2.11210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811692/
https://www.ncbi.nlm.nih.gov/pubmed/33274857
http://dx.doi.org/10.1002/acr2.11210

Ejemplares similares